Shopping Cart
- Remove All
- Your shopping cart is currently empty
BRD5631 is an autophagy enhancer that operates through an mTOR-independent pathway. It influences several cellular disease phenotypes associated with autophagy, such as protein aggregation, cell survival, bacterial replication, and inflammatory cytokine production. BRD5631 can serve as a valuable tool for studying the role of autophagy in cellular homeostasis and disease. [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 2.033 € | 10-14 weeks | |
50 mg | 2.645 € | 10-14 weeks | |
100 mg | 3.344 € | 10-14 weeks |
Description | BRD5631 is an autophagy enhancer that operates through an mTOR-independent pathway. It influences several cellular disease phenotypes associated with autophagy, such as protein aggregation, cell survival, bacterial replication, and inflammatory cytokine production. BRD5631 can serve as a valuable tool for studying the role of autophagy in cellular homeostasis and disease. [1]. |
In vitro | BRD5631 treatment (10 μM, 48 hours) elevates LC3-II levels in HeLa cells, indicating an enhancement in autophagosome formation. This activity aligns with the observed increase in autolysosome numbers in the mCherry-GFP-LC3 assay [1], suggesting BRD5631 promotes autophagy not by directly inhibiting mTOR or its signaling pathway but through alternative mechanisms. Additionally, BRD5631 reduces IL-1β secretion via an autophagy-dependent process, underscoring its potential as a modulator of autophagy-related functions [1]. |
Molecular Weight | 501.62 |
Formula | C30H35N3O4 |
Cas No. | 2446154-91-0 |
Relative Density. | 1.21 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.